MDRNA Nasal Spray Gets FDA Nod

Luke Timmerman6/9/09

Bothell, WA-based MDRNA (NASDAQ: MRNA) said today that a generic calcitonin nasal spray for osteoporosis has received FDA approval, and has been introduced to the market. The Bothell, WA-based company sold the product in March to Woodcliff Lake, NJ-based Par Pharmaceutical (NYSE: PRX), although MDRNA still stands to receive an undisclosed profit share from the product over the next five years. MDRNA has switched its strategy from developing nasal spray products to RNA interference technology.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.